Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Aligning Findings with Diagnosis: A Self-Consistent Reinforcement Learning Framework for Trustworthy Radiology Reporting
arXiv:2601.03321v2 Announce Type: replace-cross Abstract: Multimodal Large Language Models (MLLMs) have shown strong potential for radiology report generation, yet their clinical translation is hindered by architectural heterogeneity and the prevalence of factual hallucinations. Standard supervised fine-tuning often fails to strictly align linguistic outputs with visual evidence, while existing reinforcement learning approaches struggle with either prohibitive computational costs or limited exp
-
Omics in Hepatocellular
-
Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions
Ann Med. 2026 Dec;58(1):2607229. doi: 10.1080/07853890.2025.2607229. Epub 2025 Dec 26.ABSTRACTBACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remaining the predominant etiological factors. Chronic viral infection not only drives carcinogenesis but also reshapes the hepatic immune microenvironment, profoundly influencing the efficacy and safety of immunotherapy.RECENT ADVANCES:
Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions
Ann Med. 2026 Dec;58(1):2607229. doi: 10.1080/07853890.2025.2607229. Epub 2025 Dec 26.
ABSTRACT
BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remaining the predominant etiological factors. Chronic viral infection not only drives carcinogenesis but also reshapes the hepatic immune microenvironment, profoundly influencing the efficacy and safety of immunotherapy.
RECENT ADVANCES: Immune checkpoint inhibitors (ICIs) have revolutionized systemic therapy for advanced HCC, with agents targeting PD-1/PD-L1 demonstrating clinical benefit. Combination strategies - such as ICIs with anti-angiogenic therapies, multikinase inhibitors, or locoregional treatments - have shown synergistic efficacy and are now standard of care in certain settings. For virus-related HCC, antiviral therapy improves immune responsiveness and reduces risks such as HBV reactivation, underscoring the need for integrated management.
FUTURE PERSPECTIVES: Emerging therapeutic approaches include next-generation immune checkpoints (e.g. TIM-3, LAG-3, TIGIT), bispecific antibodies, cellular therapies (CAR-T, TCR-T, TILs), and tumor vaccines targeting viral or tumor-associated antigens. Advances in biomarker discovery, including circulating tumor DNA, immune signatures, and microbiome modulation, are expected to guide personalized treatment. Integration of multi-omics and clinical data will further refine patient selection and optimize treatment sequencing.
CONCLUSION: Immunotherapy offers new hope for patients with virus-related HCC, but challenges remain in response heterogeneity, resistance, and toxicity. Individualized strategies that combine immunotherapy with effective antiviral management and biomarker-|guided patient selection are essential. Continued translational and clinical research into virus-immune-tumor interactions will enable safer, more effective, and more durable treatment outcomes, ultimately transforming HCC into a more manageable disease.
PMID:41454610 | PMC:PMC12777805 | DOI:10.1080/07853890.2025.2607229
-
cs.AI, q-bio.NC updates on arXiv.org
-
ValuePilot: A Two-Phase Framework for Value-Driven Decision-Making
arXiv:2512.13716v1 Announce Type: new Abstract: Personalized decision-making is essential for human-AI interaction, enabling AI agents to act in alignment with individual users' value preferences. As AI systems expand into real-world applications, adapting to personalized values beyond task completion or collective alignment has become a critical challenge. We address this by proposing a value-driven approach to personalized decision-making. Human values serve as stable, transferable signals th
ValuePilot: A Two-Phase Framework for Value-Driven Decision-Making
-
cs.AI, q-bio.NC updates on arXiv.org
-
Why Text Prevails: Vision May Undermine Multimodal Medical Decision Making
arXiv:2512.13747v1 Announce Type: cross Abstract: With the rapid progress of large language models (LLMs), advanced multimodal large language models (MLLMs) have demonstrated impressive zero-shot capabilities on vision-language tasks. In the biomedical domain, however, even state-of-the-art MLLMs struggle with basic Medical Decision Making (MDM) tasks. We investigate this limitation using two challenging datasets: (1) three-stage Alzheimer's disease (AD) classification (normal, mild cognitive i
Why Text Prevails: Vision May Undermine Multimodal Medical Decision Making
-
Omics in Gastric
-
Development, advancement, and clinical integration of artificial intelligence technology in gastric cancer
Chin Med J (Engl). 2025 Nov 28;138(24):3332-50. doi: 10.1097/CM9.0000000000003922. Online ahead of print.ABSTRACTPersonalized medicine for gastric cancer continues to face numerous challenges, primarily due to the complexity of clinical decision making and the difficulty of integrating multimodal data. Artificial intelligence (AI), with its powerful capabilities in feature learning and pattern recognition, is emerging as a key technology to overcome these barriers. It provides critical support i
Development, advancement, and clinical integration of artificial intelligence technology in gastric cancer
Chin Med J (Engl). 2025 Nov 28;138(24):3332-50. doi: 10.1097/CM9.0000000000003922. Online ahead of print.
ABSTRACT
Personalized medicine for gastric cancer continues to face numerous challenges, primarily due to the complexity of clinical decision making and the difficulty of integrating multimodal data. Artificial intelligence (AI), with its powerful capabilities in feature learning and pattern recognition, is emerging as a key technology to overcome these barriers. It provides critical support in areas such as early screening, histological subtyping, prediction of treatment response, and prognostic risk stratification. This review examines the application of AI in diagnosing and treating gastric cancer, with particular attention to the current mainstream AI methodologies, including feature engineering and deep learning and the rapidly evolving pretrained foundation models and multimodal large models. With the integration of medical images, digital pathology, multiomics data, and structured clinical information, AI systems are increasingly effective at capturing tumor heterogeneity and supporting complex clinical decisions in real time. On the one hand, task-specific models have demonstrated excellent performance in subtyping, staging, and prognosis assessment. On the other hand, the rise of foundation models and general-purpose large models is redefining the limits of AI in cross-task transfer, complex reasoning, and human-machine interaction. These technologies hold promise in addressing key obstacles such as data scarcity, modality heterogeneity, and fragmented clinical workflows, offering a feasible path toward a unified and efficient AI-driven diagnostic and therapeutic system for gastric cancer. As technological maturity progresses alongside the development of robust safety and ethical frameworks, AI is expected to evolve from a static auxiliary interpretation tool into an intelligent decision-making platform capable of semantic understanding, dynamic feedback, and multidisciplinary collaboration-therefore playing a pivotal role across the full spectrum of precision medicine in gastric cancer.
PMID:41400327 | PMC:PMC12721780 | DOI:10.1097/CM9.0000000000003922
-
cs.AI, q-bio.NC updates on arXiv.org
-
Integrating Genomics into Multimodal EHR Foundation Models
arXiv:2510.23639v2 Announce Type: replace-cross Abstract: This paper introduces an innovative Electronic Health Record (EHR) foundation model that integrates Polygenic Risk Scores (PRS) as a foundational data modality, moving beyond traditional EHR-only approaches to build more holistic health profiles. Leveraging the extensive and diverse data from the All of Us (AoU) Research Program, this multimodal framework aims to learn complex relationships between clinical data and genetic predispositio
Integrating Genomics into Multimodal EHR Foundation Models
-
cs.AI, q-bio.NC updates on arXiv.org
-
Integrating Genomics into Multimodal EHR Foundation Models
arXiv:2510.23639v1 Announce Type: cross Abstract: This paper introduces an innovative Electronic Health Record (EHR) foundation model that integrates Polygenic Risk Scores (PRS) as a foundational data modality, moving beyond traditional EHR-only approaches to build more holistic health profiles. Leveraging the extensive and diverse data from the All of Us (AoU) Research Program, this multimodal framework aims to learn complex relationships between clinical data and genetic predispositions. The